These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11873076)

  • 1. HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy: relationship with outpatient care patterns.
    Laine C; Zhang D; Hauck WW; Turner BJ
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):270-4. PubMed ID: 11873076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users.
    Laine C; Hauck WW; Turner BJ
    Med Care; 2002 Oct; 40(10):976-95. PubMed ID: 12395030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
    J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen.
    Turner BJ; Zhang D; Laine C; Pomerantz RJ; Cosler L; Hauck WW
    J Acquir Immune Defic Syndr; 2001 May; 27(1):20-9. PubMed ID: 11404516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.
    Marimoutou C; Chêne G; Mercié P; Neau D; Farbos S; Morlat P; Ceccaldi J; Dabis F;
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):161-7. PubMed ID: 11404538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.
    Raboud JM; Loutfy MR; Su D; Bayoumi AM; Klein MB; Cooper C; Machouf N; Rourke S; Walmsley S; Rachlis A; Harrigan PR; Smieja M; Tsoukas C; Montaner JS; Hogg RS;
    BMC Infect Dis; 2010 Feb; 10():40. PubMed ID: 20184766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users.
    Turner BJ; Laine C; Cosler L; Hauck WW
    J Gen Intern Med; 2003 Apr; 18(4):248-57. PubMed ID: 12709091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis.
    Milloy MJ; Kerr T; Salters K; Samji H; Guillemi S; Montaner J; Wood E
    BMC Infect Dis; 2013 Dec; 13():565. PubMed ID: 24289651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs.
    Laine C; Hauck WW; Gourevitch MN; Rothman J; Cohen A; Turner BJ
    JAMA; 2001 May; 285(18):2355-62. PubMed ID: 11343483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti.
    Jean Louis F; Buteau J; François K; Hulland E; Domerçant JW; Yang C; Boncy J; Burris R; Pelletier V; Wagar N; Deyde V; Lowrance DW; Charles M
    PLoS One; 2018; 13(1):e0192077. PubMed ID: 29381736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
    Leierer G; Grabmeier-Pfistershammer K; Steuer A; Geit M; Sarcletti M; Haas B; Kanatschnig M; Rappold M; Zangerle R; Ledergerber B; Taylor N;
    PLoS One; 2015; 10(11):e0142923. PubMed ID: 26566025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
    de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP;
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.
    Le Moing V; Chêne G; Carrieri MP; Alioum A; Brun-Vézinet F; Piroth L; Cassuto JP; Moatti JP; Raffi F; Leport C;
    AIDS; 2002 Jan; 16(1):21-9. PubMed ID: 11741159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic.
    Purkayastha T; Wasi F; Shuter J
    AIDS Patient Care STDS; 2005 Dec; 19(12):785-93. PubMed ID: 16375610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.